February 23, 2024
PassPort Technologies, Inc.

PassPort Technologies, Inc. Initiated US Phase I Clinical Trial of Zolmitriptan
Transdermal Microporation System for the Treatment of Acute Migraine

PassPort Technologies, Inc. (PPTI), based in San Diego, initiated a US Phase 1 clinical study ofZolmitriptan PassPort® utilizing its proprietary transdermal microporation system, PassPort®
platform technology. The study objectives are to evaluate the safety of PassPort® system andpharmacokinetics to anticipate a faster onset of action
comparedtozolmitriptan

oraltablet.

Zolmitriptan,marketed under the brand name ZOMIG®, is an FDAapproved prescription medication used for treating
migraine

symptoms.

"Webelieve

ourZolmitriptan

PassPort® provides significant advantages of faster onsetof action and higher efficacy for migraine patients withsevere nausea and patients who are non-responsive to

PassPort® platform
technology will beable to provide faster
onset of action andhigher efficacy
benefiting severe
migraine patients.

oral triptans" said President and CEO Tomoyuki Fujisawa.
An open-label, randomized, crossover study consistingof 32 healthy volunteers is testing the safety, tolerability, and pharmacokinetics of Zolmitriptan
PassPort® with 3 different doses, administered to the subject's upper arm, compared to oral
administration of zolmitriptan. Additionally, the study will evaluate the transdermal administration ofa single dose at alternative sites, the subject's abdomen and upper thigh. Interim pharmacokinetic
data will be available to the public in March 2024.
About PassPort Technologies, Inc.
As a cutting-edge biotechnology entity, PPTI is committed to the swift development and patientdelivery of exceptional pharmaceuticals through the PassPort® system. The company aims toconstantly develop technologies that serve the pharmaceutical industry and broader life sciences
sectors. PPTI’s mission is to advance global health outcomes. Further details can be found athttps://passport-tech.com.
About PassPort® Technology
The PassPort® System integrates patented painless skin microporation and dry patch
formulation technologies to regulate drug delivery through the micropores created in the skin. Thisinnovative system enables transdermal delivery of not only small molecules but also peptides,proteins, and RNAs for therapeutics and infection vaccines.
Forward-Looking Statement
Except for historical information, all the statements, expectations, and assumptions containedin this Press Release are forward-looking statements. Actual results may differ materially fromthose explicit or implicit in the forward-looking statements. Important factors that could cause actual
results to differ materially include: the early phase of the clinical trial; risks associated with the drug
development process; competition; reliance on key personnel; and other risks described in other
PassPort Technologies, Inc. press releases and presentations.
■For inquiries regarding this matter, please contact:
PassPort Technologies, Inc.
Hirotoshi Adachi, Ph.D.
Chief Operating Officer
5580 Morehouse Drive, Suite 120, San Diego, CA 92121, USA
TEL: +1-858-888-4188
E-mail: info@passport-tech.com
URL: https://passport-tech.com/